LaNova Medicines and CTTQ Announces the IND Approval of Combination Therapies by NMPA

On October 9, 2024 LaNova Medicines Ltd. reported that the investigational new drug (IND) for LM-108 in combination with CTTQ’s benmelstobart injection/penpulimab, has been approved by China NMPA (Press release, LaNova Medicines, OCT 9, 2024, View Source [SID1234656018]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

LM-108 is the targeted monoclonal antibody independently developed by LaNova Medicines; benmelstobart injection is an innovative humanized anti-PD-L1 monoclonal antibody; and penpulimab is a novel differentiated anti-PD-1 monoclonal antibody.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!